Scott R, et al. - In this study, the investigators studied comparison of the effectiveness and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in subjects with type 2 diabetes and mild renal insufficiency. For a period of 24 weeks, patients with HbA1c ≥7.0 to ≤9.5% and estimated glomerular filtration rate ≥60 to <90 mL/min/1.73m² on metformin ± sulfonylurea were randomized to sitagliptin 100 mg or dapagliflozin 5 mg titrated to 10 mg once daily. The resulting observation included mild renal insufficiency and inadequate glycaemic control on metformin ± sulfonylurea, sitagliptin treatment resulted in greater improvement in glycaemic control compared with dapagliflozin and was generally well tolerated in participants with type 2 diabetes.